Abstract
Background: Infants born near the limit of viability are at high risk for death or adverse neurodevelopmental outcomes. It is unclear whether these outcomes have improved over the past 15 years. Aim: To determine if death and neurodevelopmental impairment have declined over the past 15 years in infants born at 22 to 24 weeks' gestation. Study design: Retrospective cohort study. Subjects: We identified infants born at 22 to 24 weeks' gestation in our center in two epochs: 1998-2004 (Epoch 1) and 2005-2011 (Epoch 2). Outcome measures: The primary outcome, death or neurodevelopmental impairment, was evaluated at 17-25 months' corrected gestational age with neurologic exams and Bayley Scales of Infant Development. Perinatal characteristics, major morbidities, and outcomes were compared between epochs. Results: Birth weight and gestational age were similar between 170 infants in Epoch 1 and 187 infants in Epoch 2. Mortality was significantly lower in Epoch 2, 55% vs. 42% (p = 0.02). Among surviving infants, late-onset sepsis (p < 0.01), bronchopulmonary dysplasia (p < 0.01), and surgical necrotizing enterocolitis (p = 0.04) were less common in Epoch 2. Neurodevelopmental impairment among surviving infants declined from 68% in Epoch 1 to 47% in Epoch 2, p = 0.02. Odds of death or NDI were significantly lower in Epoch 2 vs. Epoch 1, OR = 0.31 (95% confidence interval; 0.16, 0.58). Conclusion: Risk of death or neurodevelopmental impairment decreased over time in infants born at 22 to 24 weeks' gestation.
Original language | English |
---|---|
Pages (from-to) | 5-8 |
Number of pages | 4 |
Journal | Early Human Development |
Volume | 95 |
DOIs | |
State | Published - Apr 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 Elsevier Ireland Ltd.
Funding
Dr. Younge received support from National Institutes of Health ( 5T32HD043728-10 ). Dr. Smith received support from the National Institutes of Health and the National Center for Advancing Translational Sciences ( HHSN267200700051C , HHSN275201000003I and UL1TR001117 ); he also receives research support from industry for neonatal and pediatric drug development ( www.dcri.duke.edu/research/coi.jsp ). Dr. Cotten received support from National Institutes of Health ( 5U10 HD040492-10 ).
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | 5T32HD043728-10 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development | T32HD060558 |
National Center for Advancing Translational Sciences (NCATS) | 5U10 HD040492-10, HHSN267200700051C, UL1TR001117, HHSN275201000003I |
Keywords
- Extremely premature infants
- Mortality
- Neurodevelopmental outcomes
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Obstetrics and Gynecology